Patient Education This article is tailored for patients. Refer your patients to this article for them to learn more about their condition. Financial Resilience in Health: Smart Budgeting for Medical Prosperity Everyone wants to live a healthy life, but sometimes our bodies throw us a curveball. Whether it's unexpected issues or managing
Cognitive Behavioral Therapy In Patients With Insomnia And Chronic Fatigue
Cognitive Behavioral Therapy In Patients With Insomnia And Chronic Fatigue Overview This study delves into the relationship between insomnia, chronic fatigue, and the response to cognitive behavioral therapy for insomnia (CBT-I). The research, a secondary analysis of data from a community-based randomized controlled trial, encompassed 1717 participants with self-reported insomnia. The primary
Chemotherapy-Induced Thrombocytopenia in Nasopharyngeal Carcinoma
Chemotherapy-Induced Thrombocytopenia in Nasopharyngeal Carcinoma Overview This study aimed to investigate serious chemotherapy-induced thrombocytopenia (CIT) in nasopharyngeal carcinoma (NPC), focusing on its incidence, consequences, and predictors. The retrospective analysis of NPC patients from 2013 to 2015 revealed a 5.21% incidence of serious chemotherapy-induced thrombocytopenia. Patients experiencing severe thrombocytopenia had notably worse long-term prognoses,
Endocrine Therapy Outcomes In Senior Breast Cancer Patients
Endocrine Therapy Outcomes In Senior Breast Cancer Patients Overview This study investigated the management of early-stage, hormone receptor-positive, and human epidermal growth factor receptor 2 negative (HR+/HER2−) breast cancer in older women aged 70 to 90 years between 2010 and 2015. Specifically, it focused on patients who underwent lumpectomy and omitted radiation
Hepatocellular Carcinoma Treatment Outcomes: The Influence Of Butyrate Producers
Hepatocellular Carcinoma Treatment Outcomes: The Influence Of Butyrate Producers Overview In a retrospective multi-center study involving 747 patients with advanced hepatocellular carcinoma (HCC) treated with a combination therapy of atezolizumab and bevacizumab, the influence of butyric acid-producing enterobacteria on treatment outcomes was investigated. Previous research has established a link between the gut
Non-Invasive Breast Carcinoma Treatment Outcomes
Non-Invasive Breast Carcinoma Treatment Outcomes Overview Non-invasive breast carcinoma, distinct from invasive forms, can lead to local recurrence post-surgery, potentially progressing to invasive carcinoma and distant metastasis, impacting breast cancer prognosis. This study, involving 93 cases among 872 primary breast cancers, assessed outcomes. Surgical interventions, radiation, and endocrine therapy were common treatments.
Control of Allergic Rhinitis and Asthma Test: A COSMIN Analysis
Control of Allergic Rhinitis and Asthma Test: A COSMIN Analysis Overview The Control of Allergic Rhinitis and Asthma Test (CARAT) serves as a patient-reported outcome measurement (PROM) to evaluate the management of asthma and allergic rhinitis (AR) within a 4-week timeframe. This systematic review aimed to assess CARAT's measurement properties. Adhering to
Pilonidal Sinus Disease And Carcinoma Prevalence
Pilonidal Sinus Disease And Carcinoma Prevalence Overview This study aimed to evaluate survival and recurrence rates in pilonidal sinus disease (PSD) carcinoma. A retrospective analysis of global literature identified 140 cases published between 1900 and 2022. Survival rates were 61.7% at 3 years, 59.8% at 5 years, and 53.2% at 10 years.
Sintilimab and Docetaxel Treatment Comparison in Advanced Lung Cancer
Sintilimab and Docetaxel Treatment Comparison in Advanced Lung Cancer Lung cancer is the leading cause of cancer death worldwide. In China, it is estimated that there were 815,563 new cases of lung cancer and 714,699 deaths in 2020. Squamous-cell non-small-cell lung cancer (sqNSCLC) accounts for about 30% of all NSCLC cases.
Tislelizumab Treatment And Quality Of Life In Lung Cancer Patients
Tislelizumab Treatment And Quality Of Life In Lung Cancer Patients Overview In the Phase 3 trial RATIONALE-303 (NCT03358875), the study evaluated the health-related quality of life (HRQoL) among patients with advanced non-small cell lung cancer (NSCLC) who were treated with either tislelizumab or docetaxel. The assessment utilized three measurement instruments: EORTC QLQ-C30,
